Additional costimulatory immune checkpoints like OX40 (TNFRSF4/CD134), the T cell counterpart of OX40L (TNFSF4/CD252) induced during late T cell activation phases has been considered by https://www.glenmarkpharma.com/ (anti-OX40, GBR 830), https://www.kyowakirin.com/ (anti-OX40, KHK 4083) and https://www.kymab.com/ (anti-OX40L, KY1005) for the treatment of ulcerative colitis, although the emphasis of these products is to target Th2 mediated allergic disease. This evidence concerns the gene TNFRSF4 and allergic disease.